Literature DB >> 11336975

Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog.

C Lu1, A P Li.   

Abstract

Induction of P450 isoforms 1A (CYP1A) and 3A (CYP3A) by model inducers dexamethasone, omeprazole and rifampin was evaluated in primary cultured hepatocytes from man and laboratory animals. Inducer-specific species-differences were observed. Results with human hepatocytes from six human donors consistently show that both rifampin and dexamethasone were inducers of CYP3A activity (measured as testosterone 6beta-hydroxylase activity), with rifampin being more potent. Conversely, in rat hepatocytes, dexamethasone was a potent CYP3A inducer while rifampin was not an inducer. Rifampin but not dexamethasone induced CYP3A in minipig and beagle dog hepatocytes. Omeprazole was a potent inducer of CYP1A activity (measured as ethoxyresorufin-O-deethylase activity) in human, beagle dog and minipig hepatocytes, and not an inducer in rat hepatocytes. The species-differences observed suggest that human hepatocytes represent the most appropriate preclinical experimental system for the evaluation of P450 induction in human.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336975     DOI: 10.1016/s0009-2797(01)00162-4

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  22 in total

Review 1.  Porcine cytochrome P450 3A: current status on expression and regulation.

Authors:  Martin Krøyer Rasmussen
Journal:  Arch Toxicol       Date:  2020-03-14       Impact factor: 5.153

Review 2.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

3.  CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats.

Authors:  Ye Xu; Yi-Fan Zhang; Xiao-Yan Chen; Da-Fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2017-12-28       Impact factor: 6.150

Review 4.  CYP induction-mediated drug interactions: in vitro assessment and clinical implications.

Authors:  Jiunn H Lin
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

5.  Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.

Authors:  Zufei Zhang; Muhammad Farooq; Bhagwat Prasad; Sue Grepper; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2015-03-23       Impact factor: 3.922

6.  Gene expression and immunochemical localization of major cytochrome P450 drug-metabolizing enzymes in bovine nasal olfactory and respiratory mucosa.

Authors:  Varsha Dhamankar; Mahfoud Assem; Maureen D Donovan
Journal:  Inhal Toxicol       Date:  2015-11-16       Impact factor: 2.724

7.  Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.

Authors:  Joel O Olubodun; Hermann R Ochs; Lisa L von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

8.  Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures.

Authors:  C Shen; Q Meng; G Zhang; W Hu
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

9.  Micropatterned cell-cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues.

Authors:  Cheri Y Li; Kelly R Stevens; Robert E Schwartz; Brian S Alejandro; Joanne H Huang; Sangeeta N Bhatia
Journal:  Tissue Eng Part A       Date:  2014-04-28       Impact factor: 3.845

10.  Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.

Authors:  Sumanta Kumar Goswami; Bora Inceoglu; Jun Yang; Debin Wan; Sean D Kodani; Carlos Antonio Trindade da Silva; Christophe Morisseau; Bruce D Hammock
Journal:  Toxicol Appl Pharmacol       Date:  2015-11-10       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.